30 Supplemental Digital Content 1. Characteristics of antiretroviral-experienced persons with HIV aged <25 years who initiated integrase inhibitor-based antiretroviral therapy, 2011-2017, DC Cohort (n=141).
Total sample (n=141)
Virally suppressed at INSTI initiation (n=49)†
Not virally suppressed at INSTI initiation (n=92)†
n (%) n (column %) n (column %) p Age (years), median (IQR) 19.9 (16.3-22.4) 19.6 (16.1-22.7) 20.0 (16.4-22.2) 0.82
0-12 years 21 (14.9) 8 (16.3) 13 (14.1)
13-17 years 30 (21.3) 12 (24.5) 18 (19.6)
18-24 years 90 (63.8) 29 (59.2) 61 (66.3)
Male sex‡ 84 (59.6) 30 (61.2) 54 (58.7) 0.77
Race/ethnicity§ 0.71¶
Non-Hispanic Black 123 (89.1) 41 (87.2) 82 (90.1)
Non-Hispanic white 5 (3.6) 3 (6.4) 2 (2.2)
Hispanic 5 (3.6) 1 (2.1) 4 (4.4)
Other 5 (3.6) 2 (4.3) 3 (3.3)
Mode of HIV transmission§
0.30
Perinatal 83 (62.4) 25 (54.3) 58 (66.7)
MSM 38 (28.6) 15 (32.6) 23 (26.4)
Heterosexual 12 (9.0) 6 (13.0) 6 (6.9)
Time since HIV diagnosis (years), median (IQR)
7.6 (3.4-16.3) 5.5 (2.6-13.3) 9.3 (4.1-17.2) 0.035
31
History of AIDS 71 (50.4) 15 (30.6) 56 (60.9) 0.0006
Nadir CD4 count
(cells/µL), median (IQR)
328 (136-453) 372 (297-479) 228.5 (54.5-416) 0.0006
Recent CD4 count
(cells/µL), median (IQR)§
520 (352-798) 738.5 (503-847) 443 (257-650) <0.0001
Recent CD4 count category 0.0001
>500 cells/µL 74 (54.0) 35 (76.1) 39 (42.9) 350-500 cells/µL 29 (21.2) 9 (19.6) 20 (22.0)
<350 cells/µL 34 (24.8) 2 (4.3) 32 (35.2)
Most recent HIV VL (copies/mL), median (IQR)
310 (ND- 18,997)
----
5,957 (352.5- 56,675)
----
ART regimen prior to switching to an INSTI§
0.79¶
NNRTI-based 37 (28.0) 15 (31.3) 22 (26.2)
PI-based 86 (65.2) 31 (64.6) 55 (65.5)
NNRTI+PI 2 (1.5) 0 (0) 2 (2.4)
NRTI-only 7 (5.3) 2 (4.2) 5 (6.0)
Abbreviations: INSTI, integrase inhibitor; ART, antiretroviral therapy; IQR, interquartile range; MSM, men who have sex with men; ND, not detectable; NNRTI, non-nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.
† Viral suppression was defined based on whether the most recent viral load result within six months was less than the lower limit of quantification for the specific test used, which was 20 copies/mL for all but two participants, for whom it was 75 copies/mL.
‡ Includes two male-to-female transgender persons.
32
§ Data for some participants were missing for race/ethnicity (3 missing), mode of HIV transmission (8 missing), recent CD4 count (4 missing), and ART regimen used prior to initiating an INSTI-based regimen (9 missing).
¶ P-values for race/ethnicity and ART regimen prior to switching to an INSTI were obtained using Fisher’s exact tests.